- Home
- GRAL vs PLRX Comparison
GRAL vs PLRX Comparison
Compare GRAL & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAL
- PLRX
- Stock Information
- Founded
- GRAL 2016
- PLRX 2015
- Country
- GRAL United States
- PLRX United States
- Employees
- GRAL 1000
- PLRX N/A
- Industry
- GRAL
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- GRAL
- PLRX Health Care
- Exchange
- GRAL NYSE
- PLRX Nasdaq
- Market Cap
- GRAL 1.6B
- PLRX 77.3M
- IPO Year
- GRAL N/A
- PLRX 2020
- Fundamental
- Price
- GRAL $41.07
- PLRX $1.40
- Analyst Decision
- GRAL Buy
- PLRX Hold
- Analyst Count
- GRAL 3
- PLRX 10
- Target Price
- GRAL $31.50
- PLRX $9.79
- AVG Volume (30 Days)
- GRAL 1.3M
- PLRX 1.6M
- Earning Date
- GRAL 08-12-2025
- PLRX 08-06-2025
- Dividend Yield
- GRAL N/A
- PLRX N/A
- EPS Growth
- GRAL N/A
- PLRX N/A
- EPS
- GRAL N/A
- PLRX N/A
- Revenue
- GRAL $130,711,000.00
- PLRX N/A
- Revenue This Year
- GRAL $19.52
- PLRX N/A
- Revenue Next Year
- GRAL $20.37
- PLRX N/A
- P/E Ratio
- GRAL N/A
- PLRX N/A
- Revenue Growth
- GRAL 30.47
- PLRX N/A
- 52 Week Low
- GRAL $12.33
- PLRX $1.10
- 52 Week High
- GRAL $63.99
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- GRAL N/A
- PLRX 54.68
- Support Level
- GRAL N/A
- PLRX $1.13
- Resistance Level
- GRAL N/A
- PLRX $1.27
- Average True Range (ATR)
- GRAL 0.00
- PLRX 0.11
- MACD
- GRAL 0.00
- PLRX 0.02
- Stochastic Oscillator
- GRAL 0.00
- PLRX 90.00
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.